Clinical trial NCT06971848: Evaluation of Skin Tests in Biotherapy Allergies
Official title: Evaluation of Skin Tests in Biotherapy Allergies
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Melanoma Neoplasms
Small Cell Bronchial Carcinomas
Bronchial Carcinoma
Pleural Mesothelioma
Hodgkin&#39;s Lymphoma
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Myeloma
AL Amyloidosis
Hepatocarcinoma
Colorectal Cancer
Esophageal Squamous Cell Carcinoma
Heart Cancer
Cholangiocarcinoma
Colorectal Adenocarcinoma
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2025-05-14
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases. In recent years, these biotherapies have notably emerged in the treatment of cancers and hematologic disorders. As such, most patients with cancers or hematologic diseases will likely receive a biotherapy as part of their care pathway.

These biotherapies are associated with various side effects, including hypersensitivity or allergic reactions, which are often poorly characterized in clinical trials. These reactions manifest as symptoms without specific dermatologic or allergologic semiology (such as itching, erythema, shortness of breath, sometimes digestive issues, or discomfort, and in some cases, an anaphylactic reaction).

Unlike other treatments, such as antibiotics and neuromuscular blockers, there are currently no guidelines on the concentrations to use in skin tests for biotherapies. We propose conducting prospective clinical research to scientifically establish the concentrations to be used when investigating hypersensitivity to a biotherapy, in line with best practice recommendations for drug skin testing.


Eligibility criteria: Inclusion Criteria :

* Patient treated with one of the biotherapies under study (Atezolizumab 1200 mg, Nivolumab 480 mg, Obinutuzumab 100 mg, Durvalumab 1500 mg, Pembrolizumab 200 mg, Daratumumab 1800 mg, Cemiplimab 3500 mg) and who has received at least two injections of the biotherapy without suspected allergic side effects.
* Subjects covered by or having the rights to medical care assurance
* Written informed consent obtained from subject
* If applicable, treatment with corticosteroids and H1 antihistamines by systemic route (IV or oral) which may be discontinued at least one week before performing the tests (Inhaled corticosteroids are allowed).

Exclusion Criteria:

* Presence of local or diffuse dermatological lesions (e.g., psoriasis, eczema, ...) that could interfere with the interpretation of skin tests.
* Poor understanding of the French language
* Pregnancy, breastfeeding
* Persons in detention by judicial or administrative decision
* Person admitted to a health or social establishment for purposes other than research
* Person subject to a legal protection measure

Primary outcomes:
measure: maximum usable concentration considered non-irritant
timeFrame: Day 1
Secondary outcomes:
measure: possible occurrence of a delayed reaction at 48 hours post-testing
timeFrame: Day 2
measure: possible occurrence of a delayed reaction at one week post-testing
timeFrame: Day 7
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU Angers
Study officials:
affiliation: University Hospital, Angers
name: Martine MORISSET
role: PRINCIPAL_INVESTIGATOR
References: